1Schwenke DC (1998) Aging, menopause, and free radicals. Semin Reprod Endocrinol 16, 281–308.
2Geelen P, Lorga Filho A, Primo J, et al. (1997) Experience with implantable cardioverter defibrillator therapy in elderly patients. Eur Heart J 18, 1339–1342.
3Reaven PD, Napoli C, Merat S, et al. (1999) Lipoprotein modification and atherosclerosis in aging. Exp Gerontol 34, 527–537.
4Khalil A, Jay-Gerin JP, Fulop T, et al. (1998) Age-related increased susceptibility of high-density lipoproteins (HDL) to in vitro oxidation induced by gamma-radiolysis of water. FEBS Lett 435, 153–158.
5Khalil A, Wagner JR, Lacombe G, et al. (1996) Increased susceptibility of low-density lipoprotein (LDL) to oxidation by gamma-radiolysis with age. FEBS Lett 392, 45–48.
6Gowri MS, Van der Westhuyzen DR, Bridges SR, et al. (1999) Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol 19, 2226–2233.
7Zago V, Sanguinetti S, Brites F, et al. (2004) Impaired high density lipoprotein antioxidant activity in healthy postmenopausal women. Atherosclerosis 177, 203–210.
8deGoma EM, deGoma RL & Rader DJ (2008) Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 51, 2199–2211.
9Camont L, Chapman MJ & Kontush A (2011) Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med 17, 594–603.
10Barter PJ, Nicholls S, Rye KA, et al. (2004) Antiinflammatory properties of HDL. Circ Res 95, 764–772.
11Seres I, Paragh G, Deschene E, et al. (2004) Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp Gerontol 39, 59–66.
12Berrougui H, Isabelle M, Cloutier M, et al. (2007) Age-related impairment of HDL-mediated cholesterol efflux. J Lipid Res 48, 328–336.
13Baker PW, Rye KA, Gamble JR, et al. (1999) Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J Lipid Res 40, 345–353.
14Recalde D, Ostos MA, Badell E, et al. (2004) Human apolipoprotein A-IV reduces secretion of proinflammatory cytokines and atherosclerotic effects of a chronic infection mimicked by lipopolysaccharide. Arterioscler Thromb Vasc Biol 24, 756–761.
15Loued S, Isabelle M, Berrougui H, et al. (2012) The anti-inflammatory effect of paraoxonase 1 against oxidized lipids depends on its association with high density lipoproteins. Life Sci 90, 82–88.
16Shih DM, Gu L, Xia YR, et al. (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394, 284–287.
17Deakin S, Leviev I, Gomaraschi M, et al. (2002) Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem 277, 4301–4308.
18Mackness MI, Mackness B, Durrington PN, et al. (1996) Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 7, 69–76.
19Mackness MI, Durrington PN, Ayub A, et al. (1999) Low serum paraoxonase: a risk factor for atherosclerotic disease? Chem Biol Interact , 389–397.
20Durrington PN, Mackness B & Mackness MI (2001) Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21, 473–480.
21Mackness B, Hine D, Liu Y, et al. (2004) Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun 318, 680–683.
22Marsillach J, Camps J, Ferre N, et al. (2009) Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. BMC Gastroenterol 9, 3.
23Watson AD, Navab M, Hama SY, et al. (1995) Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 95, 774–782.
24Mackness B, Durrington P, McElduff P, et al. (2003) Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107, 2775–2779.
25Robertson KS, Hawe E, Miller GJ, et al. (2003) Human paraoxonase gene cluster polymorphisms as predictors of coronary heart disease risk in the prospective Northwick Park Heart Study II. Biochim Biophys Acta 1639, 203–212.
26Deakin SP & James RW (2004) Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci (Lond) 107, 435–447.
27MacKness B, Mackness MI, Durrington PN, et al. (2000) Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. Eur J Clin Invest 30, 4–10.
28Senti M, Tomas M, Anglada R, et al. (2003) Interrelationship of smoking, paraoxonase activity, and leisure time physical activity: a population-based study. Eur J Intern Med 14, 178–184.
29Yu R, Yekta B, Vakili L, et al. (2008) Proatherogenic high-density lipoprotein, vascular inflammation, and mimetic peptides. Curr Atheroscler Rep 10, 171–176.
30Perona JS, Cabello-Moruno R & Ruiz-Gutierrez V (2006) The role of virgin olive oil components in the modulation of endothelial function. J Nutr Biochem 17, 429–445.
31Perez-Jimenez F, Alvarez de Cienfuegos G, Badimon L, et al. (2005) International conference on the healthy effect of virgin olive oil. Eur J Clin Invest 35, 421–424.
32Mata P, Alvarez-Sala LA, Rubio MJ, et al. (1992) Effects of long-term monounsaturated- vs polyunsaturated-enriched diets on lipoproteins in healthy men and women. Am J Clin Nutr 55, 846–850.
33Stock J (2011) Importance of HDL functionality to cardiovascular risk. Atherosclerosis 218, 19–20.
34Sattler W, Mohr D & Stocker R (1994) Rapid isolation of lipoproteins and assessment of their peroxidation by high-performance liquid chromatography postcolumn chemiluminescence. Methods Enzymol 233, 469–489.
35Khalil A & Fulop T (2001) A comparison of the kinetics of low-density lipoprotein oxidation induced by copper or by gamma-rays: influence of radiation dose-rate and copper concentration. Can J Physiol Pharmacol 79, 114–121.
36Pryor WA & Castle L (1984) Chemical methods for the detection of lipid hydroperoxides. Methods Enzymol 105, 293–299.
37Levine RL, Garland D, Oliver CN, et al. (1990) Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 186, 464–478.
38Gan KN, Smolen A, Eckerson HW, et al. (1991) Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 19, 100–106.
39Valiyaveettil M, Alamneh Y, Biggemann L, et al. (2011) In vitro efficacy of paraoxonase 1 from multiple sources against various organophosphates. Toxicol In vitro 25, 905–913.
40Rodrigo L, Mackness B, Durrington PN, et al. (2001) Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J 354, 1–7.
41Mackness B, Mackness MI, Arrol S, et al. (1998) Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 423, 57–60.
42Lidington EA, Moyes DL, McCormack AM, et al. (1999) A comparison of primary endothelial cells and endothelial cell lines for studies of immune interactions. Transpl Immunol 7, 239–246.
43Sofi F, Cesari F, Abbate R, et al. (2008) Adherence to Mediterranean diet and health status: meta-analysis. BMJ 337, a1344.
44Gjonca A & Bobak M (1997) Albanian paradox, another example of protective effect of Mediterranean lifestyle? Lancet 350, 1815–1817.
45Papageorgiou N, Tousoulis D, Psaltopoulou T, et al. (2011) Divergent anti-inflammatory effects of different oil acute consumption on healthy individuals. Eur J Clin Nutr 65, 514–519.
46Cockerill GW, Rye KA, Gamble JR, et al. (1995) High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 15, 1987–1994.
47Cockerill GW, Huehns TY, Weerasinghe A, et al. (2001) Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 103, 108–112.
48Morgantini C, Natali A, Boldrini B, et al. (2011) Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes 60, 2617–2623.
49Kimura T, Tomura H, Mogi C, et al. (2006) Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J Biol Chem 281, 37457–37467.
50Ng DS, Chu T, Esposito B, et al. (2008) Paraoxonase-1 deficiency in mice predisposes to vascular inflammation, oxidative stress, and thrombogenicity in the absence of hyperlipidemia. Cardiovasc Pathol 17, 226–232.
51Rasic-Milutinovic Z, Popovic T, Perunicic-Pekovic G, et al. (2012) Lower serum paraoxonase-1 activity is related to linoleic and docosahexanoic fatty acids in type 2 diabetic patients. Arch Med Res 43, 75–82.
52James RW, Leviev I & Righetti A (2000) Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 101, 2252–2257.
53Abbott CA, Mackness MI, Kumar S, et al. (1995) Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 15, 1812–1818.
54Ikeda Y, Suehiro T, Inoue M, et al. (1998) Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism 47, 598–602.
55Tomas M, Senti M, Garcia-Faria F, et al. (2000) Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 20, 2113–2119.
56Jaouad L, Milochevitch C & Khalil A (2003) PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity. Free Radic Res 37, 77–83.
57Ahmed Z, Ravandi A, Maguire GF, et al. (2002) Multiple substrates for paraoxonase-1 during oxidation of phosphatidylcholine by peroxynitrite. Biochem Biophys Res Commun 290, 391–396.
58Jaouad L, de Guise C, Berrougui H, et al. (2006) Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydyl groups. Atherosclerosis 185, 191–200.
59Garin MC, Kalix B, Morabia A, et al. (2005) Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome. J Clin Endocrinol Metab 90, 2264–2269.
60Van Lenten BJ, Hama SY, de Beer FC, et al. (1995) Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 96, 2758–2767.
61Mehdi MM & Rizvi SI (2012) Human plasma paraoxonase 1 (PON1) arylesterase activity during aging: correlation with susceptibility of LDL oxidation. Arch Med Res 43, 438–443.
62Bogani P, Galli C, Villa M, et al. (2007) Postprandial anti-inflammatory and antioxidant effects of extra virgin olive oil. Atherosclerosis 190, 181–186.
63Konstantinidou V, Covas MI, Munoz-Aguayo D, et al. (2010) In vivo nutrigenomic effects of virgin olive oil polyphenols within the frame of the Mediterranean diet: a randomized controlled trial. FASEB J 24, 2546–2557.
64Cabello-Moruno R, Perona JS, Osada J, et al. (2007) Modifications in postprandial triglyceride-rich lipoprotein composition and size after the intake of pomace olive oil. J Am Coll Nutr 26, 24–31.
65Covas MI, de la Torre K, Farre-Albaladejo M, et al. (2006) Postprandial LDL phenolic content and LDL oxidation are modulated by olive oil phenolic compounds in humans. Free Radic Biol Med 40, 608–616.
66Berrougui H, Cloutier M, Isabelle M, et al. (2006) Phenolic-extract from argan oil (Argania spinosa L.) inhibits human low-density lipoprotein (LDL) oxidation and enhances cholesterol efflux from human THP-1 macrophages. Atherosclerosis 184, 389–396.
67Connelly PW, Maguire GF, Picardo CM, et al. (2008) Development of an immunoblot assay with infrared fluorescence to quantify paraoxonase 1 in serum and plasma. J Lipid Res 49, 245–250.
68Fuhrman B & Aviram M (2002) Preservation of paraoxonase activity by wine flavonoids: possible role in protection of LDL from lipid peroxidation. Ann N Y Acad Sci 957, 321–324.
69Noll C, Hamelet J, Matulewicz E, et al. (2009) Effects of red wine polyphenolic compounds on paraoxonase-1 and lectin-like oxidized low-density lipoprotein receptor-1 in hyperhomocysteinemic mice. J Nutr Biochem 20, 586–596.
70Sviridov D, Mukhamedova N, Remaley AT, et al. (2008) Antiatherogenic functionality of high density lipoprotein: how much versus how good. J Atheroscler Thromb 15, 52–62.
71Lahoz C, Alonso R, Ordovas JM, et al. (1997) Effects of dietary fat saturation on eicosanoid production, platelet aggregation and blood pressure. Eur J Clin Invest 27, 780–787.
72Ruiz-Gutierrez V, Muriana FJ, Guerrero A, et al. (1996) Plasma lipids, erythrocyte membrane lipids and blood pressure of hypertensive women after ingestion of dietary oleic acid from two different sources. J Hypertens 14, 1483–1490.
73Alonso A, Ruiz-Gutierrez V & Martinez-Gonzalez MA (2006) Monounsaturated fatty acids, olive oil and blood pressure: epidemiological, clinical and experimental evidence. Public Health Nutr 9, 251–257.